The estimated Net Worth of Jerrold B Grossman is at least $10.4 Millón dollars as of 29 August 2024. Jerrold Grossman owns over 136,861 units of Adma Biologics Inc stock worth over $10,216,447 and over the last 11 years he sold ADMA stock worth over $0. In addition, he makes $137,205 as Vice Chairman of the Board y Co-Founder at Adma Biologics Inc.
Jerrold has made over 21 trades of the Adma Biologics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 136,861 units of ADMA stock worth $585,765 on 29 August 2024.
The largest trade he's ever made was exercising 136,861 units of Adma Biologics Inc stock on 29 August 2024 worth over $585,765. On average, Jerrold trades about 20,526 units every 117 days since 2013. As of 29 August 2024 he still owns at least 604,166 units of Adma Biologics Inc stock.
You can see the complete history of Jerrold Grossman stock trades at the bottom of the page.
Dr. Jerrold B. Grossman D.P.S serves as Vice Chairman of the Board, Co-Founder of the Company. Dr. Grossman has been a director of the Company since 2007, is the Vice Chairman of our Board and is a co-founder of the Company. Dr. Grossman has over 35 years of experience in the blood and plasma industry. He served as the Chief Executive Officer of ADMA, on a part-time basis, between 2007 and October 2011. He is the founder and Chief Executive Officer of Technomed, Inc. (formerly National Hospital Specialties), a wholesaler of specialty biological and pharmaceutical products, and has served as Chief Executive Officer of that company since 1980. Additionally, Dr. Grossman is the founder and President of GenesisBPS, a medical device firm specializing in blood collection and processing equipment, and has served as President of that company since 1990. Previously, he held positions at the New York Blood Center and Immuno-U.S., Inc. and previously served as the Chairman of the Board of Bergen Community Blood Services. Currently, Dr. Grossman is a member of the New Jersey Blood Bank Task Force and a founder and director of the New Jersey Association of Blood Bank Professionals. He was a founder and former director of Pascack Bancorp, Inc., which was acquired by Lakeland Bancorp, Inc. in January 2016, and is currently a member of the Corporate Advisory Council of Lakeland Bancorp Inc. Dr. Grossman has also provided consulting services to various government agencies and international organizations. He received a B.A. in Economics and Finance from Fairleigh Dickinson University, an M.B.A. from Fairleigh Dickinson University, and his D.P.S. in Business Management from Pace University. Dr. Grossman is the father of Adam S. Grossman, our President and Chief Executive Officer. He was chosen to serve on the Board because of his role as our co-founder and past Chief Executive Officer, as well as his more than 35 years of experience serving a variety of companies and associations in the blood and plasma industry.
As the Vice Chairman of the Board y Co-Founder of Adma Biologics Inc, the total compensation of Jerrold Grossman at Adma Biologics Inc is $137,205. There are 6 executives at Adma Biologics Inc getting paid more, with Adam Grossman having the highest compensation of $1,702,020.
Jerrold Grossman is 72, he's been the Vice Chairman of the Board y Co-Founder of Adma Biologics Inc since . There are 4 older and 8 younger executives at Adma Biologics Inc. The oldest executive at Adma Biologics Inc is Dr. James Mond, 74, who is the Exec. VP, Chief Scientific Officer & Chief Medical Officer.
Jerrold's mailing address filed with the SEC is 465 New Jersey 17 S, Ramsey, NJ 07446, United States.
Over the last 11 years, insiders at Adma Biologics Inc have traded over $43,950,328 worth of Adma Biologics Inc stock and bought 17,510,201 units worth $56,736,742 . The most active insiders traders include Advisors Llcperceptive Life..., Ag Biotest Pharmaceuticals ... y Divestiture Trust Biotest. On average, Adma Biologics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $7,366,858. The most recent stock trade was executed by Lawrence P. Guiheen on 9 September 2024, trading 9,000 units of ADMA stock currently worth $97,200.
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Adma Biologics Inc executives and other stock owners filed with the SEC include: